Bio Nano Consulting
(BNC), the specialist bionanotechnology product development consultancy,
today announced that it has commenced a project with international T cell measurement
company, Oxford Immunotec. BNC is applying its expertise in nano-characterisation
to assist Oxford Immunotec in a project related to its novel Enzyme-Linked ImmunoSPOT
(ELISPOT) system. As specialists in bio-nanotechnology, BNC is able to utilise
the world-leading nano-characterisation facilities at the Institute of Biomedical
Engineering, Imperial College London.
Oxford Immunotec is commercialising a diagnostic test to detect tuberculosis
(TB) based on its patented T-SPOT technology, effectively providing a new way
to diagnose and monitor this deadly disease. The World Health Organization (WHO)
has estimated that almost 1.6 million deaths resulted worldwide from TB in 2005.
The developing field of bionanotechnology promises great advances in medicine,
particularly in the areas of diagnostics and therapeutics. By collaborating
with Oxford Immunotec, BNC is facilitating the development of precise, accurate
techniques to diagnose and monitor infection and disease.